Main Street Financial Solutions LLC Makes New Investment in Zoetis Inc. $ZTS

Main Street Financial Solutions LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 53,144 shares of the company’s stock, valued at approximately $3,819,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. BlackRock Inc. lifted its position in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. J. Stern & Co. LLP boosted its stake in Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. State Street Corp grew its holdings in Zoetis by 0.8% in the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after purchasing an additional 149,382 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

ZTS opened at $74.04 on Wednesday. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $160.48. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market capitalization of $30.60 billion, a price-to-earnings ratio of 12.20, a P/E/G ratio of 1.28 and a beta of 0.73. The firm’s fifty day moving average price is $76.01 and its two-hundred day moving average price is $98.13.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Barclays dropped their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. TD Cowen decreased their target price on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. UBS Group decreased their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Citigroup dropped their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Finally, Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.